Imaging-based PRediction of Eligibility for ChemoImmunotherapy in reSEctable NSCLC, iPRECISE

Inclusion Criteria: * Age: 18 years or older. * Diagnosis: Histologically or cytologically confirmed non-small cell lung cancer (NSCLC). * Staging: Resectable NSCLC of stage IIIA or lower. * Treatment Plan: Planned to receive neoadjuvant chemoimmunotherapy before surgery according to standard clinical practice. * Performance Status: Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Informed Consent: Able and willing to provide written informed consent after receiving a detailed explanation of the study. Exclusion Criteria: * No Measurable Lesion: Participants must have at least one measurable lesion (\>= 10 mm on spiral/multidetector computed tomography). * Prior Malignancy: History of another malignancy within 5 years before enrollment (excluding adequately treated basal cell skin carcinoma or cervical carcinoma in situ). * Neurological/Psychiatric Conditions: History of clinically significant uncontrolled seizures, CNS disease, or psychiatric disorders that may interfere with study participation or consent. * Contrast Allergy: History of severe allergic reaction to iodinated CT contrast media. * Renal Impairment: Acute renal failure or moderate to severe renal impairment (CrCl \< 45 mL/min/1.73 m² or serum creatinine \> 1.5x upper limit of normal). * Recent Surgery: Major surgery within 4 weeks of enrollment or incomplete recovery from major surgery. * Pregnancy/Nursing: Currently pregnant or breastfeeding; women of childbearing potential without a negative baseline pregnancy test. * Contraception: Men or women of childbearing potential unwilling to use appropriate contraception during the study.